<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739748</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17300520</org_study_id>
    <nct_id>NCT04739748</nct_id>
  </id_info>
  <brief_title>Prognostic Biomarkers in Predicting Mortality in Respiratory Patients With Ventilator-Associated Pneumonia</brief_title>
  <official_title>Prognostic Biomarkers in Predicting Mortality in Respiratory Patients With Ventilator-Associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate prognostic efficiency RDW and NLR for mortality&#xD;
      prediction in respiratory patients with VAP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ventilator-associated pneumonia (VAP) is the most common nosocomial infection. VAP continues&#xD;
      to be a leading cause of morbidity and mortality in the nosocomial setting. Red cell&#xD;
      distribution width (RDW) and neutrophil-lymphocyte ratio (NLR) are prognostic factors to&#xD;
      mortality in different diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2018</start_date>
  <completion_date type="Actual">December 7, 2019</completion_date>
  <primary_completion_date type="Actual">December 7, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>45 days</time_frame>
    <description>The number of patients who not Survive after developing ventilator-associated pneumonia in their stay in the Respiratory Intensive Care Unit.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">136</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Respiratory ICU patient</arm_group_label>
    <description>patient in RICU that developed ventilator-associated pneumonia</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>complete blood picture</intervention_name>
    <description>Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).</description>
    <arm_group_label>Respiratory ICU patient</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with the clinical suspicion of VAP in the Respiratory ICU were included in the&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Respiratory failure needs mechanical ventilator support &gt; 48 hrs. VAP was defined as&#xD;
             an acute lower respiratory tract infection in mechanically ventilated patient &gt; 48 hrs&#xD;
             with a new or progressing infiltrate on chest radiograph and who met at least two of&#xD;
             the following clinical criteria: body temperature &gt;38°C or &lt;36°C with no other&#xD;
             recognized cause, white blood cell count &gt;10,000 /mm3 or &lt;5000 /mm3, or a&#xD;
             macroscopically purulent tracheal aspirate&#xD;
&#xD;
          -  Only the first VAP episode was included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neutropenia (&lt; 500 cells/ml) before the development of VAP.&#xD;
&#xD;
          -  Conditions are known to influence total and differential WBC counts such as chronic&#xD;
             inflammatory conditions, hematologic disorders, history of chemotherapy, or&#xD;
             radiotherapy within 4 weeks before enrollment.&#xD;
&#xD;
          -  Conditions are known to affect RDW as anemia due to nutritional deficiency (ie, iron,&#xD;
             vitamin B12, and folic acid).&#xD;
&#xD;
          -  Patients with HIV/AIDS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chest Department-faculty of medicine-Assuit university</name>
      <address>
        <city>Assuit</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Huang KT, Tseng CC, Fang WF, Lin MC. An early predictor of the outcome of patients with ventilator-associated pneumonia. Chang Gung Med J. 2010 May-Jun;33(3):274-82.</citation>
    <PMID>20584505</PMID>
  </results_reference>
  <results_reference>
    <citation>Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002 Apr 1;165(7):867-903. Review.</citation>
    <PMID>11934711</PMID>
  </results_reference>
  <results_reference>
    <citation>Bello S, Fandos S, Lasierra AB, Mincholé E, Panadero C, Simon AL, Gavin O, De Pablo F, Menendez R, Torres A. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin. Respir Med. 2015 Sep;109(9):1193-206. doi: 10.1016/j.rmed.2015.07.003. Epub 2015 Jul 14.</citation>
    <PMID>26205553</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Nermeen Aly Mahmoud Abdel Aleem</investigator_full_name>
    <investigator_title>lecture in Faculty of medicine,Assiut University</investigator_title>
  </responsible_party>
  <keyword>Red cell distribution width</keyword>
  <keyword>neutrophil-lymphocyte ratio</keyword>
  <keyword>Intensive care units</keyword>
  <keyword>Respiratory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

